Errata - English

Line 3 of System suitability: Change
[Note—The relative retention times of aniline and p-toluidine are about 4.1 and 5.1 min, respectively.]
to:
[Note—The relative retention times of aniline and p-toluidine are 0.8 and 1.0, respectively.]

Equation in Analysis: Change
Result = (r_U/r_S) × (C_S/C_U) × (Mr₁/Mr₂) × 100
to:
Result = (r_U/r_S) × (C_S/C_U) × 100
AND
In the variable definition list: Delete
Mr₁ = molecular weight of milrinone free base, 211.22
Mr₂ = molecular weight of milrinone lactate, 151.16

Line 1 of Sample solution: Change
1.1 µg/mL of sodium fluoride
to:
0.5 µg/mL of fluoride ion
AND
In the variable definition list in Analysis: Change
C_U = nominal concentration of sodium fluoride in the Sample solution (µg/mL)
to:
C_U = nominal concentration of fluoride ion in the Sample solution (µg/mL)

(Note: This errata applies to the new USP-NF ONLINE platform only.)
Line 1 of Standard solution: Change
1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Doxazosin Related Compound C RSUSP Doxazosin Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole Related Compound I RS in Diluent
to:
1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Miconazole Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole Related Compound I RS in Diluent
AND
In the first variable definition list in Analysis: Change
C_S = concentration of USP Doxazosin Related Compound C RS, USP Doxazosin Related Compound F RS, USP Miconazole Related Compound I RS, or USP Miconazole Nitrate RS in the Standard solution (µg/mL)
to:
C_S = concentration of USP Miconazole Related Compound C RS, USP Miconazole Related Compound F RS, USP Miconazole Related Compound I RS, or USP Econazole Nitrate RS in the Standard solution (µg/mL)

Line 1 of Medium B: Change
Kreb's salt solution containing 0.3% (v/v) human serum albumen
to:
Krebs' salt solution containing 0.3% (v/v) human serum albumin
AND
Line 1 of Medium C: change
Kreb's salt solution containing 0.3% (v/v) human serum albumen
to:
Krebs' salt solution containing 0.3% (v/v) human serum albumin

In the second variable definition in Analysis: Change
r_U = peak response of chloroindolinone or ziprasidone related compound F from the Sample solution
to:
r_U = peak response of chloroindolinone, ziprasidone related compound F, or any unspecified impurity from the Sample solution

Line 1 of Plastic Additives/Reference solutions/Reference solution I: Change
0.24 mg/mL of USP Plastic Additive 4 RS prepared in the Solvent mixture
to:
0.24 mg/mL of USP Plastic Additive 4 RS prepared in methylene chloride
AND
Line 1 of Reference solution J: Change
0.24 mg/mL of USP Plastic Additive 5 RS prepared in the Solvent mixture
to:
0.24 mg/mL of USP Plastic Additive 5 RS prepared in methylene chloride
AND
Line 1 of Poly(ethylene-vinyl acetate)/Polyvinyl chloride, plasticized/Reference solutions U, V, W: Change
0.1-mg/mL solutions
to:
10.0-mg/mL solutions

(Note: This errata applies to the new USP-NF ONLINE platform only.)
Line 4 of USP Reference Standards <11>: Change
USP Doxazosin Related Compound C RS
to:
USP Miconazole Related Compound C RS
AND
Line 7 of USP Reference Standards <11>: Change
USP Econazole Nitrate RS
to:
USP Miconazole Related Compound F RS

(Note: This errata applies to the new USP-NF ONLINE platform only.)
Line 1 of System suitability solution: Change
0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Econazole Nitrate RS in Diluent.
to:
0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Miconazole Related Compound F RS in Diluent.

Line 1 of Sample solution: Change
Polydextrose, calculated on the anhydrous and ash-free basis, in Mobile phase
to:
Polydextrose in Mobile phase
AND
Line 1 of Acceptance criteria: Change
NLT 90.0%
to:
NLT 90.0% on the anhydrous and ash-free basis

Change
Standard solution: 4.0 mg/mL of USP Polydextrose RS, calculated on the anhydrous and ash-free basis, in Mobile phase
Sample solution: 4.0 mg/mL of Hydrogenated Polydextrose, calculated on the anhydrous and ash-free basis, in Mobile phase
to:
Standard solution: 4.0 mg/mL of USP Polydextrose RS in Mobile phase
Sample solution: 4.0 mg/mL of Hydrogenated Polydextrose in Mobile phase

Line 2 of USP Eszopiclone Related Compound A RS:
[Note—This material may be available in the free base or salt form.]
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide.
C₁₇H₁₇ClN₆O₄ 404.81
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1).
C₁₇H₁₇ClN₆O₄ · C₇H₅ClO 561.38
to:
[Note—This material may be available in the free base or salt form.]
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide.
C₁₇H₁₇ClN₆O₄ 404.81
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoate salt (1:1).
C₁₇H₁₇ClN₆O₄ · C₇H₅ClO₂ 561.38

Line 2: Change
Samples: Standard solution and Sample solution
to:
Samples: Standard solution A and Sample solution
AND
In the variable definition list: Change
r_S = peak response of erythritol from the Standard solution
C_S = concentration of USP Erythritol RS in the Standard solution (mg/mL)
to:
r_S = peak response of erythritol from Standard solution A
C_S = concentration of USP Erythritol RS in Standard solution A (mg/mL)

Line 3 of Application/4.: Change
proscribed
to:
prescribed
AND
Line 3 of Description of Polymers Contained in <661.1>/Polyethylenes: Change
Low-density polypropylene (LDPE)
to:
Low-density polyethylene (LDPE)
AND
Line 6 of Description of Polymers Contained in <661.1>/Polypropylene: Change
0.3% polypropylene
to:
0.3%. Polypropylene
AND
Line 3 of Description of Polymers Contained in <661.1>/Polyethylene Terephthalate and Polyethylene Terephthalate G: Change
1,4-cyclohexaemimethanol
to:
1,4-cyclohexanedimethanol

Line 2 of USP Eszopiclone Related Compound A RS:
[Note—This material may be available in the free base or salt form.]
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide.
C₁₇H₁₇ClN₆O₄ 404.81
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1).
C₁₇H₁₇ClN₆O₄ · C₇H₅ClO 561.38
to:
[Note – This material may be available in the free base or salt form.]
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide.
C₁₇H₁₇ClN₆O₄ 404.81
6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoate salt (1:1).
C₁₇H₁₇ClN₆O₄ · C₇H₅ClO₂ 561.38

In the second Calculate statement: Change
chloroindolinone and ziprasidone related compound F
to:
chloroindolinone, ziprasidone related compound F, and any individual unspecified impurity
AND
In the second variable definition list: Change
F = relative response factor for chloroindolinone or ziprasidone related compound F from Table 3
to:
F = relative response factor for chloroindolinone or ziprasidone related compound F or any individual unspecified impurity from Table 3

Line 2 of USP Doxepin Related Compound C RS: Change
(E,Z)-3-(Dibenzo[b,e]oxepin-11(6H-ylidene)-N-methyl-propoan-1-amine.
to:
(E,Z)-3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N-methylpropan-1-amine hydrochloride.

Line 2 of USP Miconazole Related Compound C RS: Change
2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethan-1-amine.
C₁₅H₁₃Cl₄NO 365.08
to:
2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethan-1-amine hydrochloride.
C₁₅H₁₃Cl₄NO · HCl 401.53

In the second variable definition list: Change
C_S2 = concentration of USP Cholesterol RS in the Standard solution (mg/mL)
to:
C_S2 = concentration of USP Cholesterol RS in the System suitability solution (mg/mL)

Line 1 of paragraph 3: Change
general information chapter Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers <601>),
to:
general chapter Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests <601>),

Line 1: Change
Chewable Tablets respond to the Identification test under Isosorbide Dinitrate Tablets.
to:
Transfer a suitable quantity of finely powdered Tablets to a glass-stoppered centrifuge tube. Add 10 mL of sodium hydroxide solution (1 in 250), shake to wet the powder, then add 15 mL of solvent hexane, and again shake. Centrifuge the mixture, and transfer the upper phase to a beaker. Evaporate the solvent, and dry the residue in vacuum over anhydrous calcium chloride at room temperature for 16 hours: the IR absorption spectrum of a suitable solution in chloroform of the residue so obtained exhibits maxima only at the same wavelengths as that of a similar preparation from the residue obtained from USP Diluted Isosorbide Dinitrate RS.

Line 4 of paragraph 3 of 3.2 Combined Validation of Accuracy and Precision: Change
validate evaluate
to:
validate
AND
Variable definition in paragraph 6 of 3.2 Combined Validation of Accuracy and Precision: Change
Z²(1 + P)/2 = standard normal
to:
Z²(1 + P)/2 = the square of the standard normal

Line 2 of USP Argatroban Related Compound B RS: Change
Ethyl (2R,4R)-1-[N⁸-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate hydrochloride.
C₁₅H₂₈N₆O₅ ∙ HCl 408.88
to:
Ethyl (4R)-1-[N⁸-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate dihydrochloride.
C₁₅H₂₈N₆O₅ ∙ 2HCl 445.34

Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer solution—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7.
Mobile phase—Mix 350 mL of water, 100 mL of Buffer solution, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see System Suitability under Chromatography <621>).
Internal standard solution—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container.
Standard preparation—Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of Mobile phase, shake for 30 minutes, dilute with Mobile phase to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of Internal standard solution and 4 mL of dilute Buffer solution (1 in 10). Cool to room temperature, dilute with Mobile phase to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter.
AND
Add
Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the resolution, R, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.]
AND
Line 1 of Procedure: Change
Proceed as directed for Procedure in the Assay under Diluted Isosorbide Dinitrate.
to:
Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.